Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

NCT07101614 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT07101614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Lead sponsor
Shengjing Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
November 30, 2028
Enrollment
125 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer